BRUSSELS and SAN FRANCISCO, May 19, 2025

布鲁塞尔和旧金山，2025年5月19日

– UCB, a global biopharmaceutical company, and Domino Data Lab, provider of a leading data science platform trusted by the world’s largest enterprises, today announced a strategic collaboration aimed at modernizing a Statistical Computing Environment (SCE) for the life sciences industry. This joint effort aims to transform the legacy SCE into unified, scalable, and flexible platforms to meet the evolving demands of clinical research, regulatory compliance, and efficient data analysis..

全球生物制药公司优时比（UCB）与提供领先数据科学平台的Domino Data Lab今日宣布达成战略合作伙伴关系，旨在为生命科学行业现代化统计计算环境（SCE）。这一合作努力将把传统的统计计算环境转变为统一、可扩展且灵活的平台，以满足临床研究、法规遵从和高效数据分析不断变化的需求。

The two companies will work together to implement a modern cloud-enabled environment that integrates diverse analytical tools, such as SAS, R, and Python, within a unified framework. This platform will leverage Domino’s expertise in cloud technologies and open-source support, combined with UCB’s deep clinical research and regulatory knowledge.

两家公司将共同合作，实施一个现代化的云赋能环境，将各种分析工具（如 SAS、R 和 Python）整合到一个统一的框架中。该平台将利用 Domino 在云技术和开源支持方面的专业能力，并结合 UCB 深厚的临床研究和监管知识。

Together, this effort aims to enhance research capabilities and maintain compliance with industry standards like GxP, FDA 21 CFR Part 11, and GDPR. .

共同努力，旨在提高研究能力，并确保符合GxP、FDA 21 CFR Part 11和GDPR等行业标准。

“At UCB, we believe that innovation thrives through collaboration, and this partnership exemplifies our commitment to evolving and pushing the boundaries of what’s possible in life sciences. By harnessing advanced technologies to modernize our statistical computing environment and combining our expertise with Domino’s cutting-edge platform, we aim to accelerate the development of innovative therapies for people living with severe diseases,” said Mike Branson, SVP, Head Biometrics and Data Science, UCB.

“在UCB，我们相信创新通过合作得以蓬勃发展，这一合作伙伴关系体现了我们对推动生命科学领域可能性边界的承诺。通过利用先进技术来现代化我们的统计计算环境，并将我们的专业知识与Domino的前沿平台相结合，我们旨在加速为患有严重疾病的人群开发创新疗法，”UCB生物统计与数据科学高级副总裁迈克·布兰森表示。

He added, “This new SCE will embed critical metadata and workflow management to enable searchable, responsible data re-use, accelerating our cutting-edge Data Science and enabling more efficient drug development and evidence-based decision making.”.

他补充道：“这个新的SCE将嵌入关键的元数据和工作流管理，以实现可搜索、负责任的数据再利用，加速我们前沿的数据科学，并使药物开发更高效以及基于证据的决策更加便捷。”

The collaboration is aligned with UCB’s broader scientific innovation strategy, which includes leveraging pathways, populations, and technology platforms to uncover the root biological causes of diseases, deepen understanding of patient populations, and accelerate R&D pipelines.

该合作与UCB更广泛的科学创新战略保持一致，其中包括利用途径、人群和技术平台来揭示疾病的生物学根本原因，加深对患者群体的理解，并加速研发管线。

'We're proud to partner with UCB to help patients get new therapies faster,” said Nick Elprin, CEO and co-founder of Domino Data Lab. “Together, we aim to lead the way in modernizing Statistical Computing Environments to accelerate clinical development with greater speed, flexibility, and confidence.”.

“我们很自豪能与UCB合作，帮助患者更快获得新疗法，”Domino Data Lab首席执行官兼联合创始人尼克·埃尔普林表示。“我们共同致力于在现代化统计计算环境方面引领潮流，以更快速、灵活和可靠的方式加速临床开发。”

The modernized SCE will bring immediate benefits to researchers, data scientists, and patients by providing streamlined access to state-of-the-art tools. Enhancing UCB’s capabilities in this way should expedite the development of differentiated therapies, offering faster, more tailored treatment options for those living with severe diseases.

现代化的SCE将通过提供对最先进的工具的简化访问，为研究人员、数据科学家和患者带来直接的好处。通过这种方式增强UCB的能力，应该会加速差异化疗法的开发，为患有严重疾病的患者提供更快、更个性化的治疗选择。

Additionally, the integration of advanced data science will enable more efficient clinical studies, leveraging large-scale data analysis to enhance predictions about efficacy and tolerability..

此外，先进数据科学的整合将实现更高效的临床研究，利用大规模数据分析来增强对疗效和耐受性的预测。

This collaboration also emphasizes UCB and Domino’s shared commitment to driving innovation across the life sciences industry. By contributing to initiatives like

此次合作还强调了UCB和Domino共同致力于推动生命科学行业的创新。通过参与像这样的举措，

PHUSE

PHUSE

, and the

，以及

SCE Coalition

SCE联盟

, the partnership aims to foster open-source principles, challenge industry norms, and establish global standards for efficient and compliant statistical environments. Together, UCB and Domino are not only advancing their own operations but also paving the way for broader industry transformation.

，该合作伙伴关系旨在促进开源原则，挑战行业规范，并建立高效且合规的统计环境的全球标准。UCB和Domino不仅推动了自身的运营进步，还为更广泛的行业转型铺平了道路。

About UCB

关于UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9 000 people in approximately 40 countries, the company generated revenue of € 6.1 billion in 2024.

优时比公司（UCB），位于比利时布鲁塞尔（www.ucb.com），是一家全球生物制药公司，专注于发现和开发创新药物及解决方案，以改变免疫系统或中枢神经系统严重疾病患者的生活。该公司在约40个国家拥有9000多名员工，并于2024年实现了61亿欧元的收入。

UCB is listed on Euronext Brussels (symbol: UCB). .

UCB在布鲁塞尔泛欧交易所上市（股票代码：UCB）。

About Domino Data Lab

关于Domino Data Lab

Domino Data Lab empowers the largest data-driven enterprises to build and operate data science at scale. Domino’s Enterprise Data Science Platform provides an integrated experience encompassing analysis and reporting, collaboration, and governance. With Domino, global enterprises can develop better medicines, grow more productive crops, develop more competitive products, and more.

Domino Data Lab 赋能最大的数据驱动型企业大规模构建和运营数据科学。Domino 的企业数据科学平台提供了一个涵盖分析与报告、协作及治理的集成体验。通过 Domino，全球企业可以开发更好的药物、种植更高产的作物、研发更具竞争力的产品等等。

Founded in 2013, Domino is backed by Sequoia Capital, Coatue Management, NVIDIA, Snowflake, and other leading investors. Learn more at .

Domino 成立于 2013 年，得到了红杉资本、Coatue Management、NVIDIA、Snowflake 和其他领先投资者的支持。更多信息请访问 。

domino.ai

多米诺人工智能

.

。

For more information

更多信息请参阅

Investor Relations, UCB

投资者关系，UCB

Antje Witte

安特耶·维特

T +32.2.559.94.14

电话：+32.2.559.94.14

email antje.witte@ucb.com

电子邮件 antje.witte@ucb.com

Head of Global R&D and Business Communications, UCB

全球研发和商务传播主管，UCB

Scott Fleming

斯科特·弗莱明

T +447702777378

电话：+447702777378

email scott.fleming@ucb.com

电子邮件 scott.fleming@ucb.com

For Domino Data Lab

适用于Domino数据实验室

David Conner

大卫·康纳

T +1 415-907-0400

电话：+1 415-907-0400

email david.conner@dominodatalab.com

电子邮件 david.conner@dominodatalab.com

Forward looking statements

前瞻性声明

This document contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management.

本文件包含前瞻性陈述，包括但不限于包含“潜在”、“相信”、“预期”、“预计”、“打算”、“计划”、“寻求”、“估计”、“可能”、“将”、“继续”等词语及类似表达的陈述。这些前瞻性陈述基于管理层当前的计划、估计和信念。

All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results.

所有声明，除历史事实声明外，均可能被视为前瞻性声明，包括收入、营业利润率、资本支出、现金、其他财务信息、预期法律、仲裁、政治、监管或临床结果或实践以及其他此类估计和结果。

By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document..

由于此类前瞻性陈述的性质，其并不能保证未来的表现，并且受到已知和未知的风险、不确定性和假设的影响，这可能导致UCB的实际结果、财务状况、业绩或成就，或行业结果，与本文件中包含的此类前瞻性陈述所明示或暗示的任何未来结果、业绩或成就存在重大差异。

Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring,  retention and compliance of its employees.

可能导致此类差异的重要因素包括但不限于：战争、疫情和恐怖主义的全球蔓延及其影响、总体地缘政治环境、气候变化、总体经济、商业和竞争状况的变化、无法获得必要的监管批准或未能在可接受的条件或预期时间内获得批准、与研发相关的成本、UCB在研产品或开发中产品的前景变化、未来司法裁决或政府调查的影响、安全性、质量、数据完整性或制造问题、供应链中断和业务连续性风险；潜在或实际的数据安全和隐私泄露，或我们信息技术系统的中断、产品责任索赔、对产品或候选产品专利保护的挑战、来自其他产品（包括生物类似药或颠覆性技术/商业模式）的竞争、法律法规的变化、汇率波动、税法及其执行的变动或不确定性，以及员工的招聘、留任和合规问题。

There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans.

无法保证在研发管线中会发现或识别出新的产品候选者，也无法保证现有产品的新增适应症能够被开发并获得批准。从概念到商业产品的推进过程充满不确定性；临床前结果不能保证产品候选者在人体中的安全性和有效性。

So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpr.

到目前为止，人体的复杂性无法在计算机模型、细胞培养系统或动物模型中重现。完成临床试验和获得产品上市监管批准的时间在过去有所不同，UCB预计会有类似的不确定性。

Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise.

鉴于这些不确定性，公众被提醒不要对这些前瞻性声明给予任何过度依赖。这些前瞻性声明仅在本文件发布之日作出，并不反映上述不断演变的事件或风险以及任何其他不利因素的潜在影响，除非另有说明。

The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB..

公司继续认真跟进事态发展，评估这些事件对UCB的财务影响（如有）。

UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations..

UCB明确表示，除非适用法律法规要求，否则不承担更新本文件中任何前瞻性陈述的义务，无论该等更新是为了确认实际结果，还是为了报告或反映与其前瞻性陈述相关的任何变化，或反映作为该等陈述基础的事件、条件或情况的任何变化。